Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(14%)
Results Posted
33%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
6
86%

Phase Distribution

6

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Not yet recruiting1
Terminated1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
75.0%
Most Advanced
Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

not_yet_recruiting114%
terminated114%
unknown114%
active_not_recruiting114%
completed343%

Recent Activity

1 active trials
Showing 5 of 7
not_yet_recruitingphase_1

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

NCT07297160
active_not_recruiting

De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma

NCT04638465
completedphase_1

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells

NCT00078520
completedphase_1

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

NCT00058799
completedphase_1

Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis

NCT00838565
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07297160Phase 1

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

Not Yet Recruiting
NCT04638465

De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma

Active Not Recruiting
NCT00078520Phase 1

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells

Completed
NCT00058799Phase 1

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

Completed
NCT00838565Phase 1

Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis

Completed
NCT03038971Phase 1

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

Terminated
NCT02134262Phase 1

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Unknown

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7